Image-Guided Hypofractionated Proton Therapy in Early-Stage Non-Small Cell Lung Cancer: A Phase 2 Study.
10/11/2020
/
Publications
/
Hypofractionation
Survival
22 patients with T1 to T2 N0M0 NSCLC received image-guided hypofractionated PBT to a total dose 48 GyRBE in 4 fractions for peripheral lesions and 60 GyRBE in...
Proton therapy following induction chemotherapy for pediatric and adolescent nasopharyngeal carcinoma.
07/09/2019
/
Publications
/
Chemotherapy
Survival
A study by the Jacksonville group. Seventeen patients with nonmetastatic nasopharyngeal carcinoma underwent double-scattered proton therapy. With the median...
Preliminary result of definitive radiotherapy in patients with NSCLC who have underlying idiopathic pulmonary fibrosis
01/01/2019
/
Publications
/
Survival
Idiopathic pulmonary fibrosis (IPF) is associated with fatal complications after radiotherapy (RT) for lung cancer patients. This study evaluated 264 patients...
Radiation for ETMR: LR and case series of patients treated with PT.
11/11/2018
/
Publications
/
Survival
Embryonal tumors with multilayered rosettes (ETMRs) are aggressive tumors that typically occur in young children. This study reported the outcomes of seven...
Reirradiation for locoregionally recurrent non-small cell lung cancer.
08/08/2018
/
Publications
/
Reirradiation
IMPT
Survival
In the context of definitive retreatment, increasing reRT dose can potentially improve OS and offer a chance of cure, particularly in patients with limited loco...
Long-term survival outcomes and quality of life of image-guided proton therapy for operable stage I non-small cell lung cancer: A phase 2 study.
06/05/2024
/
Publications
/
Survival
Quality of life
Toxicity
This study from Japan reported clinical outcomes of 43 patient with operable stage IA or IB NSCLC treated with a dose of 66 GyRBE in 10 fractions for peripheral...
A bibliometric analysis of cardiotoxicity in cancer radiotherapy.
06/05/2024
/
Publications
/
Quality of life
Survival
Radiation induced heart disease (RIHD) significantly impacts the long-term survival and quality of life of cancer survivors as one of the most devastating...
Proton Beam Therapy for Children With Neuroblastoma: Experiences From the Prospective KiProReg Registry.
31/01/2021
/
Publications
/
Survival
44 patients with high-risk (n = 39) or intermediate-risk (n = 5) neuroblastoma were treated with protons. With a median follow-up of 27.6 months, eight patients...
Proton Therapy for Pediatric Ependymoma: Mature Results from a Bicentric Study.
01/07/2021
/
Publications
/
Survival
Toxicity
386 children with nonmetastatic grade II/III intracranial ependymoma received proton therapy. With the median follow-up of 5 years, the 7-year local control...
Effects of lymphopenia on survival in proton therapy with chemotherapy for non-small cell lung cancer.
16/03/2023
/
Publications
/
Chemotherapy
Survival
With data of 41 patients with stage III NSCLC who received PBT of 74 GyE with concurrent chemotherapy, this study reported that bone V5-20 and lung V5-50 were...
Cookies policy
If you continue browsing this website, you agree to the use of cookies in order to provide you with services and offers tailored to your own interests.
Manage your cookie preferences
Respect for your privacy is still a priority for us at IBA.
Functional cookies ensure that the website runs smoothly. They cannot be turned off. By setting your preferences, you can turn the use of these cookies on and off on our website, although these settings will only be valid on the device you are currently using.